APM seems to gain some reversal volume as all the support levels are smashed and the stock is making a bounce back.
Aptorum Shares Rise After FDA Orphan Drug Tag For Repurposed Compound For Pediatric Cancer The FDA has granted Orphan Drug Designation to Aptorum Group Limited (NASDAQ: APM) SACT-1, a repurposed small molecule compound for Neuroblastoma. Aptorum Group plans to file an Investigational New Drug Application (IND) to commence a Phase 1b/2a trial for SACT-1 in...
test Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. Its...
Hi Guys, see analysis. Thank you
Descending triangle, Confirmed Pros Descending volume Volume spike on break out PPS under 50MA No data on 200MA No data on 250MA RS below 0 and descending Overall bearish No support under 1,37$ Price Target PT1 = 2,11 (filled) PT2 = 1,37 Could see lower
touch the resistance and have the potential to rise.
Hello, Be sure to comment, follow, like, and check out my profile for more trade ideas! About Aptorum Group Aptorum Group Limited (Nasdaq:APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group’s current drug pipeline includes indications in orphan diseases, infectious...